Initial treatment of the 124 patients with MZL included in this analysis
| . | N . | Splenic Subtype . | Leukemic Subtype . | Nodal Subtype . | Disseminated Subtype . | P Value . |
|---|---|---|---|---|---|---|
| No. patients | 124 | 59 | 8 | 37 | 20 | |
| Initial treatment: | .0001 | |||||
| No treatment | 22 | 12 (20%) | 7 (87.5%) | 2 (5%) | 1 (5%) | |
| Surgery alone | 17 | 13 (22%) | 0 | 4 (11%) | 0 | |
| Single agent | 35 | 16 (27%) | 1 (12.5%) | 8 (22%) | 10 (50%) | |
| CHOP-like regimen | 28 | 11 (19%) | 0 | 11 (30%) | 6 (30%) | |
| High-dose therapy | 22 | 7 (12%) | 0 | 12 (32%) | 3 (15%) | |
| Complete response | 43 (35%) | 15 (28%) | 0 | 24 (69%) | 4 (25%) | .0001 |
| Progression | 57 (46%) | 21 (36%) | 3 (37.5%) | 24 (65%) | 9 (45%) | <.05 |
| Median TTP (y) | 6.9 | 5.6 | 1.3 | 1.1 | .02 | |
| Death | 34 (27%) | 15 (25%) | 1 (12.5%) | 14 (38%) | 4 (20%) | |
| Median survival (y) | 9.1 | 6.8 | 5.5 | 14.7 |
| . | N . | Splenic Subtype . | Leukemic Subtype . | Nodal Subtype . | Disseminated Subtype . | P Value . |
|---|---|---|---|---|---|---|
| No. patients | 124 | 59 | 8 | 37 | 20 | |
| Initial treatment: | .0001 | |||||
| No treatment | 22 | 12 (20%) | 7 (87.5%) | 2 (5%) | 1 (5%) | |
| Surgery alone | 17 | 13 (22%) | 0 | 4 (11%) | 0 | |
| Single agent | 35 | 16 (27%) | 1 (12.5%) | 8 (22%) | 10 (50%) | |
| CHOP-like regimen | 28 | 11 (19%) | 0 | 11 (30%) | 6 (30%) | |
| High-dose therapy | 22 | 7 (12%) | 0 | 12 (32%) | 3 (15%) | |
| Complete response | 43 (35%) | 15 (28%) | 0 | 24 (69%) | 4 (25%) | .0001 |
| Progression | 57 (46%) | 21 (36%) | 3 (37.5%) | 24 (65%) | 9 (45%) | <.05 |
| Median TTP (y) | 6.9 | 5.6 | 1.3 | 1.1 | .02 | |
| Death | 34 (27%) | 15 (25%) | 1 (12.5%) | 14 (38%) | 4 (20%) | |
| Median survival (y) | 9.1 | 6.8 | 5.5 | 14.7 |
CHOP = combination of cyclophosphamide, doxorubicin, vincristine, and prednisone; MZL = marginal zone B-cell lymphoma; TTP = time to progression.